Heidelberg Pharma AG

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

The cruciality of partnerships in business was stressed by George Badescu, chief business officer (CBO) at oncology therapies company Heidelberg Pharma AG , during a talk at the BIO-Europe Spring con

Biopharma initial public offerings may be on the rise in 2024 – and not just in the US, where much of the industry’s IPO-tracking attention is focused. Galderma S.A. revealed on 6 March that it inte